Clinical Trials Directory

Trials / Completed

CompletedNCT01033604

Glyaderm + Split Thickness Skin Graft Versus Split Thickness Skin Graft Alone in Full Thickness Skin Defects

Clinical Application of a Novel Dermal Substitute Based on Glycerol Preserved Allograft: GLYADERM

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
31 (actual)
Sponsor
University Hospital, Ghent · Academic / Other
Sex
All
Age
80 Years
Healthy volunteers
Not accepted

Summary

The application of Glyaderm for skin restoration intends to provide a more stable wound closure with enhanced pliability and function of the skin and a more favourable scar. The dermal substitute would be affordable for widespread application in full thickness skin defects and burns. Patients with burn wounds or large full thickness wounds will be evaluated before enrollment. All burn wounds that are not clearly full thickness on clinical assessment will be treated during the first 48 hours with a hydrocolloid paste and covered with a paraffin gauze dressing. This hydrocolloid paste combined with paraffin gauze will ensure maintenance of a moist wound environment for the first 48 hours prior to assessment by LDI and randomization. This is the standard treatment for all burns admitted to the Ghent Burn Centre. Wounds will be photographed on a daily basis. In order to obtain an optimal preparation for LDI, the burn wounds will be meticulously debrided during dressing changes. LDI is most reliable between 48-72 hours. Patients whose burn wounds meet the inclusion criteria, i.e. full thickness burns with LDI values \< 200 will be randomized to receive either GLYADERM and split skin graft versus split skin graft alone.

Conditions

Interventions

TypeNameDescription
PROCEDUREGlyaderm and split skin graftFull thickness defects treated with Glyaderm and split skin graft.
PROCEDURESplit skin graft alone.Full thickness defects treated with split skin graft alone.

Timeline

Start date
2007-09-01
Primary completion
2012-02-01
Completion
2012-12-01
First posted
2009-12-16
Last updated
2014-12-05

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT01033604. Inclusion in this directory is not an endorsement.